Tesaro Inc. (NASDAQ:TSRO) had its price objective increased by analysts at Robert W. Baird to $120.00 in a research note issued to investors on Monday. Robert W. Baird’s price objective would suggest a potential upside of 4.05% from the company’s current price.
Several other equities research analysts have also issued reports on TSRO. FBR & Co reaffirmed a “buy” rating on shares of Tesaro in a report on Thursday, June 30th. Zacks Investment Research raised shares of Tesaro from a “sell” rating to a “hold” rating in a report on Tuesday, July 5th. SunTrust Banks Inc. reiterated a “buy” rating and set a $91.60 target price on shares of Tesaro in a research report on Wednesday, September 14th. Wedbush reiterated a “buy” rating on shares of Tesaro in a research report on Thursday, June 30th. Finally, Credit Suisse Group AG reiterated a “buy” rating on shares of Tesaro in a research report on Friday, August 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have given a buy rating to the company’s stock. Tesaro has an average rating of “Buy” and a consensus target price of $109.76.
Shares of Tesaro (NASDAQ:TSRO) opened at 115.33 on Monday. The company’s market cap is $5.92 billion. The stock’s 50 day moving average is $97.53 and its 200 day moving average is $70.11. Tesaro has a 12 month low of $29.51 and a 12 month high of $122.89.
Tesaro (NASDAQ:TSRO) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.71) by $0.43. The company had revenue of $36.60 million for the quarter, compared to analyst estimates of $4.98 million. Tesaro had a negative net margin of 783.97% and a negative return on equity of 205.63%. During the same period in the previous year, the firm posted ($1.51) EPS. On average, analysts anticipate that Tesaro will post ($7.36) EPS for the current fiscal year.
In other news, VP Jeffrey H. Hanke sold 29,166 shares of the business’s stock in a transaction that occurred on Tuesday, August 30th. The shares were sold at an average price of $86.04, for a total value of $2,509,442.64. Following the transaction, the vice president now owns 29,166 shares in the company, valued at approximately $2,509,442.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Martin H. Jr. Huber sold 408 shares of the business’s stock in a transaction that occurred on Thursday, September 22nd. The stock was sold at an average price of $108.12, for a total transaction of $44,112.96. Following the completion of the transaction, the senior vice president now owns 1,250 shares in the company, valued at approximately $135,150. The disclosure for this sale can be found here. 40.50% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Passport Capital LLC bought a new stake in Tesaro during the second quarter valued at $61,720,000. FMR LLC raised its stake in Tesaro by 9.6% in the second quarter. FMR LLC now owns 6,097,449 shares of the biopharmaceutical company’s stock valued at $512,490,000 after buying an additional 531,892 shares in the last quarter. Pictet Asset Management Ltd. raised its stake in Tesaro by 661.3% in the second quarter. Pictet Asset Management Ltd. now owns 418,730 shares of the biopharmaceutical company’s stock valued at $19,387,000 after buying an additional 363,730 shares in the last quarter. Emerald Acquisition Ltd. bought a new stake in Tesaro during the second quarter valued at $23,685,000. Finally, Vanguard Group Inc. raised its stake in Tesaro by 11.0% in the second quarter. Vanguard Group Inc. now owns 2,216,739 shares of the biopharmaceutical company’s stock valued at $186,317,000 after buying an additional 219,902 shares in the last quarter. Hedge funds and other institutional investors own 88.81% of the company’s stock.
Tesaro Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related companies with MarketBeat.com's FREE daily email newsletter.